The First Treatment for a Rare Neurodegenerative Condition Awaits FDA Approval

Melissa Beiner, senior medical director at Biohaven, discusses spinocerebellar ataxia, the company’s therapy under priority review at the FDA to treat the condition, and why it may have the potential to benefit a number of other neurological conditions as well.